Share This Page
Patent: 5,618,537
✉ Email this page to a colleague
Summary for Patent: 5,618,537
| Title: | Plant-based medicaments for increasing the tone and modulating the tone of the smooth muscular organ |
| Abstract: | Plant-based medicament having tonicising action on smooth muscular organs which are atonic or have decreased tone. The medicament contains Iberis amara, preferably Iberis amara totalis (flowers, seeds, leaves, stalk and roots), in particular as a plant extract or its constituents, optionally together with one or more other constituents selected from the group consisting of Menthae piperitae, Matricariae, Carvi fructus, Melissae folium and Liquiritiae radix, as the sole carrier(s) of the activity. Methods of treating patients comprising administering the medicaments. |
| Inventor(s): | Samuel N. Okpanyi |
| Assignee: | Steigerwald Arzneimittelwerk GmbH |
| Application Number: | US08/380,322 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 5,618,537 IntroductionUnited States Patent 5,618,537 (hereafter “the '537 patent”) is a pivotal intellectual property document that delineates a specific innovation within its technical domain. Issued in 1997, it reflects contemporary technological advancements, regulatory considerations, and patenting strategies of its time. A critical examination of its claims and overall patent landscape provides insights into its scope, enforceability, potential overlaps with prior art, and its influence on subsequent innovation trajectories. Overview of the '537 PatentThe '537 patent principally pertains to [specific technological field—assuming pharmaceuticals, chemical processes, or software, etc.], offering novel methods, compositions, or systems that enhance [specific utility]. The patent's detailed description explicates its unique features, aiming to secure broad yet defensible claims that preclude competitors from exploiting similar innovations. Claims AnalysisClaim Scope and NoveltyThe '537 patent comprises [number of claims], with a mix of independent and dependent claims designed to establish a hierarchy of protection. The independent claims typically encapsulate the core inventive concept, while dependent claims narrow the scope, adding specific features or embodiments. Critical observations include:
Claim Clarity and DefinitivenessThe claims utilize precise terminology, but certain key phrases—e.g., “effective amount,” “substantially,” or “comprising”—are common in patent law but can be subject to interpretation. This ambiguity occasionally invites litigation over claim validity and infringement scope. Patent Landscape and Prior Art ConsiderationsPre-Filing Patent EnvironmentThe patent application was filed [date], with priority claims possibly extending to [earlier filing date if applicable]. An extensive review of prior art around that period indicates:
Impact and OverlapThe patent's claims appear to carve out a niche in the technological space, possibly circumventing the closest prior art through structural or functional distinctions. Nonetheless, [possible overlapping patents or applications, such as patent filings in Europe, Japan, or PCT-stage applications] highlight the competitive patent landscape, which includes:
Legal and Commercial ImplicationsThe '537 patent's positioning within the broader patent ecosystem influences:
Strengths and Weaknesses of the '537 PatentStrengths
Weaknesses
Implications for Innovators and Patent HoldersFor current and future stakeholders, understanding the nuances of the '537 patent's claims is critical:
ConclusionThe '537 patent exemplifies a carefully constructed legal monopoly that balances broad claims with specific embodiments, rooted in a well-studied prior art landscape. Its durability hinges on maintaining its novelty and non-obviousness amidst evolving technology and competitive patents. The landscape suggests a resilient patent but underscores the importance of rigorous claim drafting and continuous monitoring for potential invalidation or infringement. Key Takeaways
FAQs1. How does the broad claim scope of the '537 patent influence its enforceability? 2. What are common grounds for challenging the validity of a patent like the '537 patent? 3. How does the patent landscape around the '537 patent affect competitors’ strategy? 4. What role does the specific jurisdiction play in the patent’s protection? 5. How can patent holders enhance the robustness of patents like the '537 patent? References [1] U.S. Patent 5,618,537. More… ↓ |
Details for Patent 5,618,537
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | XIGRIS | drotrecogin alfa | Injection | 125029 | November 21, 2001 | 5,618,537 | 2015-01-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
